Lonza focuses on CDMO demand and sector peers, shares tracked on SIX and Xetra

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 09:53.

Lonza Group AG (CH0013841017) is one of the larger healthcare names on the SIX Swiss Exchange, active as a contract development and manufacturing organization for the pharmaceutical and biotechnology industry. The company operates in a competitive global CDMO sector alongside peers such as Catalent and Samsung Biologics, which shapes analyst views and trading in the Lonza shares on SIX and via secondary listings like Xetra.

What sector analysts highlight

Lonza is widely covered by international brokers, with consensus data on platforms such as MarketScreener showing a broad analyst base tracking the Swiss healthcare group. Analyst coverage typically emphasizes Lonza’s exposure to biologics, cell and gene therapies and small-molecule manufacturing, as well as the capital intensity of CDMO capacity expansions.

Peers like Catalent in the United States and Samsung Biologics in South Korea illustrate the global nature of the CDMO market, where capacity utilization and long-term customer contracts are key metrics discussed in research reports. For Lonza, analysts usually focus on margin development in its Biologics and Small Molecules segments and on the visibility of its long-term revenue backlog when assessing the stock.

Position in the global CDMO landscape

The CDMO sector has grown in importance as pharmaceutical and biotechnology companies increasingly outsource parts of their manufacturing and development activities to specialized partners. Lonza is positioned in this value chain with facilities spanning Europe, North America and Asia, which allows the company to serve large multinational clients and smaller biotech firms alike.

In this environment, Lonza competes not only on price but also on technology, scale and regulatory track record, with good manufacturing practice compliance being a fundamental requirement for all sites. Investors and analysts therefore monitor regulatory inspections, capacity additions and new long-term contracts as indicators of Lonza’s operational strength.

How Lonza earns its money

Lonza generates most of its revenue by providing contract development and manufacturing services for pharmaceutical and biotechnology clients, including biologics, small molecules and cell and gene therapies. The group’s Biologics segment covers antibody and protein production, while the Cell & Gene division offers viral vector manufacturing and related services.

Where the shares trade today

The Lonza shares (CH0013841017) trade on the SIX Swiss Exchange in Swiss francs, with additional trading lines such as a euro-quoted listing on Xetra for German investors. As of 2026-06-26, 09:30, the shares change hands at 579.00 euros on the Xetra-linked quotation referenced by Deutsche Börse data, reflecting Lonza’s position among larger European healthcare names.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data has been carefully researched but cannot be guaranteed for accuracy or completeness.